TrianglePUBLICATIONS · 35364421
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Eur J Cancer
- Publication date
- 2022 May
- First author
- Kudo M
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Kudo M
- type
- Author
- name
- Finn RS
- type
- Author
- name
- Edeline J
- type
- Author
- name
- Cattan S
- type
- Author
- name
- Ogasawara S
- type
- Author
- name
- Palmer DH
- type
- Author
- name
- Verslype C
- type
- Author
- name
- Zagonel V
- type
- Author
- name
- Fartoux L
- type
- Author
- name
- Vogel A
- type
- Author
- name
- Sarker D
- type
- Author
- name
- Verset G
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Kudo M
- type
- Author
- name
- Finn RS
- type
- Author
- name
- Edeline J
- type
- Author
- name
- Cattan S
- type
- Author
- name
- Ogasawara S
- type
- Author
- name
- Palmer DH
- type
- Author
- name
- Verslype C
- type
- Author
- name
- Zagonel V
- type
- Author
- name
- Fartoux L
- type
- Author
- name
- Vogel A
- type
- Author
- name
- Sarker D
- type
- Author
- name
- Verset G
- type
- Author
- bibliography ids
- nci-bib-8e04d32d4553184ec9e12caf
- book metadata
- content sha256
- 59542c3ed96c4ee2641d6a52ed76f2ae57c4e6c7f4601470a34b38befe7ac04f
- document type
- citation
- dois
- 10.1016/j.ejca.2022.02.009
- electronic publication date
- display
- 2022 Mar 29
- precision
- day
- year
- 2022
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:35364421
- immutable id
- pubmed:35364421@59542c3ed96c4ee2641d6a52ed76f2ae57c4e6c7f4601470a34b38befe7ac04f
- journal
- abbreviation
- Eur J Cancer
- issn electronic
- 1879-0852
- issn print
- 0959-8049
- issue
- Source null
- name
- European journal of cancer (Oxford, England : 1990)
- nlm unique id
- 9005373
- pages
- 1-12
- volume
- 167
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 35364421
- provenance
- batch id
- 3f4d1914d2afe41e9e70
- provider
- NCBI PubMed ESummary
- record sha256
- eb7c028a88815ddb7d5a554767ce1d58fc67b82d1b496cdc0e263253c170f5e9
- response sha256
- 0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
- retrieved at
- 2026-09-09T23:48:06.522634+00:00
- publication date
- display
- 2022 May
- precision
- month
- year
- 2022
- publication types
- Clinical Trial, Phase II
- Journal Article
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Preserved source evidence · Not medical advice